Last reviewed · How we verify

NCT06624774

Prehabilitation's Effect on Skeletal Muscle Mass in Cardiac Patients

Active, enrolled NA Last updated 3 October 2024
What this trial tests

NA trial testing Prehabilitation in Cardiovascular Diseases in 30 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
23 September 2024
Primary endpoint
27 September 2026
27 September 2026

Quick facts

Lead sponsorManchester Metropolitan University
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment30
Start date23 September 2024
Primary completion27 September 2026
Estimated completion27 September 2026
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Manchester Metropolitan University

Who can join

Adults 18 to 85, any sex, with Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will investigate the effect prehabilitation on skeletal muscle mass via a scanner.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Prehabilitation

Trials testing the same drug.

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other Manchester Metropolitan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06624774.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing